JP2012509263A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509263A5 JP2012509263A5 JP2011536395A JP2011536395A JP2012509263A5 JP 2012509263 A5 JP2012509263 A5 JP 2012509263A5 JP 2011536395 A JP2011536395 A JP 2011536395A JP 2011536395 A JP2011536395 A JP 2011536395A JP 2012509263 A5 JP2012509263 A5 JP 2012509263A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- trifluoromethyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- -1 cyano, chloro, methyl Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11533208P | 2008-11-17 | 2008-11-17 | |
| US61/115,332 | 2008-11-17 | ||
| PCT/US2009/063370 WO2010056588A1 (en) | 2008-11-17 | 2009-11-05 | Tetrasubstituted pyridazine hedgehog pathway antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509263A JP2012509263A (ja) | 2012-04-19 |
| JP2012509263A5 true JP2012509263A5 (enExample) | 2012-12-13 |
| JP5518887B2 JP5518887B2 (ja) | 2014-06-11 |
Family
ID=41722877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536395A Expired - Fee Related JP5518887B2 (ja) | 2008-11-17 | 2009-11-05 | 四置換ピリダジンヘッジホッグ経路アンタゴニスト |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8507490B2 (enExample) |
| EP (1) | EP2358698B1 (enExample) |
| JP (1) | JP5518887B2 (enExample) |
| KR (1) | KR101342184B1 (enExample) |
| CN (1) | CN102216285B (enExample) |
| AU (1) | AU2009314349B2 (enExample) |
| BR (1) | BRPI0921782A2 (enExample) |
| CA (1) | CA2743483C (enExample) |
| CY (1) | CY1113377T1 (enExample) |
| DK (1) | DK2358698T3 (enExample) |
| EA (1) | EA017386B1 (enExample) |
| ES (1) | ES2392759T3 (enExample) |
| HR (1) | HRP20120762T1 (enExample) |
| MX (1) | MX2011005177A (enExample) |
| PL (1) | PL2358698T3 (enExample) |
| PT (1) | PT2358698E (enExample) |
| SI (1) | SI2358698T1 (enExample) |
| WO (1) | WO2010056588A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200700057A (es) * | 2006-07-17 | 2008-03-05 | Nuevos derivados de piridazina | |
| JP5442717B2 (ja) | 2008-04-29 | 2014-03-12 | イーライ リリー アンド カンパニー | 二置換フタラジンヘッジホッグ経路アンタゴニスト |
| CA2742539C (en) | 2008-11-03 | 2014-05-06 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| EP2358703B1 (en) | 2008-11-17 | 2013-12-25 | Eli Lilly and Company | Tetrasubstituted pyridazines hedgehog pathway antagonists |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
| GB201309508D0 (en) | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
| US9814703B2 (en) | 2013-11-14 | 2017-11-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of BMP signaling |
| GB2528298A (en) * | 2014-07-16 | 2016-01-20 | Redx Pharma Plc | Compounds |
| CN105130980B (zh) * | 2015-09-09 | 2018-05-22 | 沈阳药科大学 | N-3-苯并咪唑噻唑胺类衍生物及其制备方法与应用 |
| CN107163028B (zh) * | 2017-05-24 | 2019-07-12 | 东南大学 | 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用 |
| CN110208424A (zh) * | 2019-06-28 | 2019-09-06 | 江苏恒生检测有限公司 | 一种农药氟啶虫酰胺中含有杂质的分析方法 |
| WO2021071981A1 (en) * | 2019-10-08 | 2021-04-15 | Skyhawk Therapeutics, Inc. | Compounds for modulating splicing |
| JP2023546536A (ja) | 2020-10-13 | 2023-11-02 | エンデバー バイオメディシンズ， インコーポレイテッド | 線維症を処置する方法 |
| EP4395890A1 (en) * | 2021-08-30 | 2024-07-10 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2025188802A1 (en) | 2024-03-05 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of improving lung function |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1293565A (en) | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
| AU717744B2 (en) | 1996-01-15 | 2000-03-30 | Janssen Pharmaceutica N.V. | Angiogenesis inhibiting pyridazinamines |
| AU768130B2 (en) | 1998-04-09 | 2003-12-04 | Johns Hopkins University School Of Medicine, The | Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways |
| US6432970B2 (en) | 1998-04-09 | 2002-08-13 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
| ATE283700T1 (de) | 1999-06-08 | 2004-12-15 | Lorantis Ltd | Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges |
| US7655674B2 (en) | 2002-04-22 | 2010-02-02 | The Johns Hopkins University | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| AU2003265853A1 (en) | 2002-08-29 | 2004-03-19 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| WO2005033288A2 (en) | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Hedgehog pathway antagonists |
| TW200533356A (en) | 2004-02-24 | 2005-10-16 | Mitsubishi Pharma Corp | Fused pyridazine derivatives |
| WO2006004589A2 (en) | 2004-05-08 | 2006-01-12 | Neurogen Corporation | 3-aryl-5,6-disubstituted pyridazines |
| AU2005282722C1 (en) | 2004-09-02 | 2011-08-18 | Curis, Inc. | Pyridyl inhibitors of hedgehog signalling |
| EP1900731A1 (de) | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
| KR101473504B1 (ko) * | 2007-03-15 | 2014-12-16 | 노파르티스 아게 | 유기 화합물 및 그의 용도 |
| CA2690378A1 (en) | 2007-06-25 | 2008-12-31 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| EP2188283B1 (en) | 2007-09-07 | 2012-08-15 | Amgen Inc. | Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling |
| JP5442717B2 (ja) | 2008-04-29 | 2014-03-12 | イーライ リリー アンド カンパニー | 二置換フタラジンヘッジホッグ経路アンタゴニスト |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| CA2742539C (en) | 2008-11-03 | 2014-05-06 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| EP2358703B1 (en) | 2008-11-17 | 2013-12-25 | Eli Lilly and Company | Tetrasubstituted pyridazines hedgehog pathway antagonists |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
-
2009
- 2009-11-05 DK DK09752059.7T patent/DK2358698T3/da active
- 2009-11-05 WO PCT/US2009/063370 patent/WO2010056588A1/en not_active Ceased
- 2009-11-05 ES ES09752059T patent/ES2392759T3/es active Active
- 2009-11-05 MX MX2011005177A patent/MX2011005177A/es active IP Right Grant
- 2009-11-05 EP EP09752059A patent/EP2358698B1/en not_active Not-in-force
- 2009-11-05 PL PL09752059T patent/PL2358698T3/pl unknown
- 2009-11-05 PT PT09752059T patent/PT2358698E/pt unknown
- 2009-11-05 JP JP2011536395A patent/JP5518887B2/ja not_active Expired - Fee Related
- 2009-11-05 CA CA2743483A patent/CA2743483C/en not_active Expired - Fee Related
- 2009-11-05 CN CN200980145554.8A patent/CN102216285B/zh not_active Expired - Fee Related
- 2009-11-05 HR HRP20120762AT patent/HRP20120762T1/hr unknown
- 2009-11-05 AU AU2009314349A patent/AU2009314349B2/en not_active Ceased
- 2009-11-05 EA EA201170699A patent/EA017386B1/ru not_active IP Right Cessation
- 2009-11-05 BR BRPI0921782A patent/BRPI0921782A2/pt not_active IP Right Cessation
- 2009-11-05 SI SI200930351T patent/SI2358698T1/sl unknown
- 2009-11-05 US US13/122,216 patent/US8507490B2/en not_active Expired - Fee Related
- 2009-11-05 KR KR1020117011148A patent/KR101342184B1/ko not_active Expired - Fee Related
-
2012
- 2012-10-25 CY CY20121101019T patent/CY1113377T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012509263A5 (enExample) | ||
| JP2012530705A5 (enExample) | ||
| JP2012507535A5 (enExample) | ||
| JP2014139226A5 (enExample) | ||
| JP2009526072A5 (enExample) | ||
| HRP20120762T1 (hr) | Tetrasupstituirani piridazini kao inhibitori hedgehog puta | |
| HRP20100477T1 (hr) | Kemijski spojevi | |
| NZ547615A (en) | Quinoline derivatives and use thereof as mycobacterial inhibitors | |
| JP2011527666A5 (enExample) | ||
| JP2015524472A5 (enExample) | ||
| JP2014507464A5 (enExample) | ||
| JP2018502877A5 (enExample) | ||
| JP2010509356A5 (enExample) | ||
| JP2012533546A5 (enExample) | ||
| JP2018507877A5 (enExample) | ||
| PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
| NZ703941A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| JP2013543896A5 (enExample) | ||
| JP2011519854A5 (enExample) | ||
| CA2579915A1 (en) | Indole derivatives and their use as inhibitors of p53-mdm2 interaction | |
| WO2009080836A3 (en) | Macrocyclic indoles as hepatitis c virus inhibitors | |
| JP2016506962A5 (enExample) | ||
| JP2019518770A5 (enExample) | ||
| MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
| MX2007010105A (es) | Derivados de 4-oxoquinazolin-3-ilbenzamida para el tratamiento de enfermedades mediadas por citocinas. |